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cDNA  Complementary DNA 
CO2  Carbon dioxide 
CSC  Cancer Stem Cells 
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IMS  Inner Mitochondrial Space 
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MFF  Mitochondrial Fission Factor 
MFN1  Mitofusin 1 
MFN2  Mitofusin 2 
mDivi-1 Mitochondrial Division Inhibitor 1 
MFF  Mitochondrial fission factor 
Mid49  Mitochondrial Dynamic protein of 49 
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RPMI  Roswell Park Memorial Institute media 
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Pancreatic cancer is a type of cancer that acquires therapeutic resistance over time. The presence 
of CSCs and epithelial-to mesenchymal transition gives it a highly aggressive profile. The 
importance of mitochondria in all cellular processes, both physiological and pathological, leads 
to consider that it has an involvement in tumor processes. The overexpression of genes involved 
in the process of pluripotency, epithelium-mesenchymal transition and in mitochondrial 
dynamics indicate a worse prognosis for these patients. Our results confirmed that CSC-
enriched samples present over-expression of pluripotency genes, this allowed to select them to 
determine the increase of mitochondrial dynamics in CSCs compared to differentiated cells, 
without being able to determine which mitochondrial activity was predominant. Epithelium-to-
mesenchyme transition allows the tumor to spread throughout the body, ending in metastasis. 
The migration process was slowed down when we treated the cells with mDivi-1 whose 
function is to inhibit DRP1, this protein involved in mitochondrial fission acts on the 
progression, migration and tumor invasion.  
 
 RESUMEN 
En cáncer de páncreas es un tipo de cancer que adquiere resistencia terapéutica con el tiempo. 
La presencia de CSCs y la transición epitelio a mesénquima le otorga un perfil altamente 
agresivo. La importancia de las mitocondrias en todos los procesos celulares, tanto fisiológicos 
como patológicos, lleva a considerar que tiene una implicación en los procesos tumorales. La 
sobreexpresión de los genes implicados el proceso de pluripotencia, transición epitelio-
mesénquima y en la dinámica mitocondrial indican un peor pronóstico para estos pacientes. 
Nuestros resultados confirmaron que las muestras enriquecidas de CSCs presentan 
sobreexpresión de los genes de pluripotencia, esto permitió seleccionarlas para determinar un 
aumento de dinámica mitocondrial en CSCs comparado con células diferenciadas, sin poder 
determinar qué actividad mitocondrial predominaba. La transición epitelio a mesénquima 
permite que el tumor se disemine por el organismo, de manera que termina en metástasis. El 
proceso migratorio se vio frenado cuando tratamos las células con mDivi-1 cuya función es 
inhibir DRP1, esta proteína implicada en la fisión mitocondrial actúa sobre la progresión, 




Based on GLOBOCAN 2018 statistics, pancreatic cancer (PC) mainly affects Asia, followed 
by Europe with a 28.9% incidence (1). Within the Spanish framework, PC is not the most 
diagnosed type of cancer, only 2.5% of tumors are diagnosed (2). However, it is the third most 
deadly cancer at 6.4% (2)(3). 
4.1. PANCREATIC CANCER 
Pancreatic ductal adenocarcinoma (PDAC) is heterogeneous and highly mutated. It begins with 
acinar-ductal metaplasia, and as genetic mutations accumulate, neoplastic intraepithelial lesions 
(PanIN) occur leading to invasive carcinoma with a largely metastatic end (4)(5)(6).  90% of 
cases arise sporadically, however, hereditary cases account for 10%. Older age, smoking, 
chronic pancreatitis, chemicals, obesity and diabetes are often the most relevant risk factors 
(5)(7)(8).  
Symptoms progress over time, in the early stages it is usually an asymptomatic disease, only 
10% of patients are diagnosed early with possible benefits of surgical resection for cure 
(5)(8)(9) However, in later stages the symptoms are more evident and this is when it is 
diagnosed, but there is no chance of a cure (5). Survival rate is low, 8% of patients achieve 5-
year survival (9). 
Molecular therapies are based on the activation and inhibition of molecules involved in 
pathways of growth, progression, invasion and metastasis (5). The first line of treatment is the 
combination of FOLFIRINOX (leucovorin, 5-FU, irinotecan and oxaliplatin) or gemcitabine 
with nab-paclitaxel, prolonging survival from 6 to 12 months (8)(9). As a second line, NAPOLI-
1-2015 (nano-liposomal irinotecan with 5-FU and leucovorin) (10).  
Many mutations have been seen in PDAC, hence its genetic instability. KRAS activation and 
CDKN2A inhibition are seen in 90-95% of cases, while TP53 inhibition is seen in 75% of cases 
(4). At the onset of the disease there is a low grade PanIN where KRAS mutation has been seen, 
so this suggests that there are early changes in tumor progression. However, TP53 and SMAD4 
mutations are seen in a high degree of PanIN and pancreatic adenocarcinoma (PAAD) (11) 




The failure of the treatment is usually due to the tumor microenvironment (TME) that favours 
the formation of an ideal niche that supports the tumor cells. In this environment, extracellular 
matrix, fibroblasts, activated pancreatic stellate cells and immune cells stand out (8). This cell 
group acts as a mechanical barrier where there is a decrease in vascularization and, therefore, 
the drugs do not reach the target cell (6). So when therapy fails, the tumor will grow back 
quickly and uncontrollably (4)(6).  
Another cause of therapeutic failure is the presence of cancer stem cells (CSCs) in tumor. These 
cells have the ability to self-renew so that they provide resistance to chemotherapy, tumor 
initiation and evasion of the primary tumor. Therefore, the prognosis of PDAC patients should 
be improve if CSCs were removed. (5)(8)(12)(13)(14). 
4.2. MITOCHONDRIAL DYNAMICS 
Mitochondria are highly dynamic organelles that participate in different functions such as 
growth, division, metabolism and apoptosis (12). They form a kind of dynamic network is 
Figure 1. Molecular pathway in pancreatic cancer. Schedule represents the different molecular pathways in each step of 
the disease. (KEGG, hsa05212) 
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formed that varies morphologically in response to cellular stimuli (12)(13). The changes in the 
morphology and content of the mitochondria are given by the mitochondrial dynamics which 
consists of the balance between fission and fusion (14). When cells do not have enough 
nutrients, mitochondrial fusion protein allows mitochondria fuse together to share nutrients and 
maintain OXPHOS. In contrast, mitochondrial fission fragments the mitochondria for 
mitochondria movement to regions of high energy demand (13). 
 
4.2.1. MOLECULAR MECHANISM  
Mitochondria is composed of two membranes; outer mitochondrial membrane (OMM) and 
inner mitochondrial membrane (IMM) between both there are inner mitochondrial space (IMS) 
(13).  In these membranes are located guanosine triphosphatases (GTPases) that regulate 
mitochondrial dynamics (15). GTPases for mitochondria fusion are: mitofusin 1 (MFN1), 
mitofusin 2 (MFN2) and optical atrophy 1 (OPA1), however, for mitochondrial fission is 
dynamine-related protein 1 (DRP1) with DRP1 protein adapters: mitochondria fission factor 
(MFF), fission protein 1 (FIS1), mitochondrial dynamic protein 49 (Mid49) and 51 (Mid51) 
(16)    
Mitochondrial fusion consists of the fusion of the OMM by the action of the MFN1 and MFN2 
followed by the fusion of the IMM mediated by OPA1 (14). This process is important for 
maintaining the quality of the mitochondria. In a situation where mitochondrial fusion 
predominates, the number of mitochondria and OXPHOS is reduced. The absence of both 
mitofusins means that there is no mitochondrial fusion, however in the absence of OPA1 the 
OMM is fused, but not the IMM, so that the cells drift into mitochondrial fission (Figure 2A) 
(17).  
Mitochondrial fission starts with the interaction of the endoplasmic reticulum (ER) and 
mitochondria, where takes place the first constriction. Likewise, DRP1, which is found in the 
cytoplasm, is recruited on the mitochondrial surface to associate with MFF, FIS1, Mid49 and 
Mid51 (14). So, DRP1 forms helical assemblies around mitochondria, but for the last excision 
step, dynamin 2 (DNM2) is necessary for severing mitochondria (14). Fission process occurs 
when there are high energy demand from the cells (Figure 2B)(18).  
MYC, mTOR (PI3K/Akt) and MAPK act on the signalling cascade of transcriptional 
coactivator peroxisome proliferator-activator receptor gamma coactivator 1 alpha (PGC1-α) 
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which promotes the expression of mitochondrial genes encoded in nucleus by activating 
transcription factors and hormone receptor to induce mitochondrial biogenesis 
(13)(19)(20)(21).  This regulation is discussed further in the following section about 
mitochondrial dynamics and cancer because these three pathways are implicated in proliferation 
and anti-apoptotic genes, therefore, tumoral progress.  
 
4.2.2. MITOCHONDRIAL DYNAMICS IN CANCER 
The energy demands of cancer cells during tumorigenesis and cancer progression induce 
changes in mitochondrial metabolism in order to support tumor proliferation and prevent 
apoptosis (13)(19). So, mitochondrial dynamics are closely related to the progression, migration 
Figure 2. Mechanism of mitochondrial dynamics.  A) Mitochondrial fusion. The amino and carboxyl terminal are 
orientated at cytosol, that allows connection between mitofusins of different mitochondrial, while the transmembrane 
region is within OMM and IMS. OPA1 isoforms are anchored in IMM and coordinate IMM fusion. OPA1 interacts with 
mitofusins to create a bridge between both membranes. B) Mitochondrial fission. DRP1 is in the cytosol and is activated 
by phosphorylation at Ser616, in this moment, it translocates to the OMM, binds to adaptors and start to form the helical 





A. P. Trotta, J. E. Chipuk, 2017 
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and invasion of tumor cells (12)(14)(22).  Increased mitochondrial fission promotes tumor 
progression by inhibiting mitochondria-dependent apoptosis and activating autophagy (12). 
While increased fusion prevents invasion and metastasis, its deficiency favours the opposite, so 
it can be considered to act as a tumor suppressor (14).  
The mutation in MAPK and PI3K-Akt or amplification of MYC influences the metabolic 
pathways by which cancer cells obtain the necessary products. MAPK pathway activate the 
signal cascade, finally, to phosphorylate to extracellular signal regulated kinase 1/2 (ERK1/2) 
and is activated. When there are KRAS mutation, activated ERK 1/2 can phosphorylate DRP1.  
DRP1 protein presents three residues that can be phosphorylated: S616 induces fission and 
S693 induces fusion, while S637 can induce both fusion and mitochondrial fission depending 
on cellular conditions (16)(18)(22). However, in the absence of KRAS the induction of 
mitochondrial fission is given by the mitogenic protein kinase (MEK) or the Raf (13)(22). On 
the other hand, mitochondrial fusion is also altered by the mutation in three pathways. The 
phosphorylation of MFN1 by ERK ½ at Tyr562 or c-Jun N-terminal kinase (Jnk) decrease the 
fusion activity, while mitochondrial fragmentation increases (Figure 3A) (16) (19).  
In solid tumor such a PC, loss of PTEN, that is an inhibitor of PI3K, induces hyperactivation of 
PI3K-Akt pathway. PI3K mutated is similar to MAPK pathway, increase mitochondrial 
fragmentation, while inhibition of PI3K increase mitochondrial fusion. (Figure 3A) This 
pathway is important in autophagy and mitophagy where dysfunctional mitochondria is 
removed  (13) 
The two pathways described above can stimulate the expression of MYC (13). MYC participates 
in mitochondrial dynamics and induce the mitochondrial fusion to promote the biosynthesis of 
metabolites which are necessary for cell growth and proliferation (19). Oncogenic MYC is an 
activator of PGC-1β expression, thus is associated with increase of mitochondria mass and 






4.3. CANCER STEM CELLS (CSCs) 
Stem cells are undifferentiated cells with unlimited capacity for proliferation and self-renewal, 
the latter process being important for tissue development and regeneration (8). In general, its 
self-renewal is kept in balance with the ability to differentiate itself through different 
mechanisms. A failure in this balance leads to many failures among which is the tumor process 
(23) The similarity between stem cells and tumor stem cells reveals that they have a similar 
metabolism (14). The Yamanaka factors (OCT4, KLF4, SOX2 and c-MYC) allow the 
reprogramming of adult cells giving rise to stem cells, these are characterized by having a lower 
Figure 3. Three signal pathways implicated in mitochondrial dynamics with migration and differentiation process. A) 
Oncogenic MAPK and PI3K pathways induce DRP1-dependent mitochondrial fission. B) MYC is regulated by MAPK and 
PI3K to finally promote mitochondrial fusion. Amplification of MYC. C) Migration cells depends of fragmented 
mitochondria D) Adult stem cells and fibroblast present fused mitochondria; however, cancer stem cells show fragmented 
mitochondria. 
A. P. Trotta, J. E. Chipuk, 2017 
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number of mitochondria and also immature (12). CSCs reactivate the MYC, SOX2, and OCT4  
genes involved in self-renewal, while the NANOG gene is related to stem cells and CSCs 
(8)(24).  The ability to induce tumors in other areas of the body is being shown to be due to this 
cell type (14).  
The heterogeneity of PDAC is due to the different subpopulations present, each with different 
phenotypes and functions (6)(8)(25). One of them are CSCs have the ability to self-renew and 
provide resistance to chemotherapy, and are responsible for tumor initiation, evasion of the 
primary tumor, survival in anoikis conditions, and migration to other regions generating 
secondary tumors. (5)(8)(25)(24)(26). 
Tumor cells require large amounts of energy for the synthesis of amino acids, lipids and nucleic 
acids, which are necessary for replication and division (12)(14). Pancreatic CSCs obtain their 
energy mostly from OXPHOS, while non-CSCs depend on glycolysis (25). The group 
discovered the importance of PGC1α in maintenance of OXPHOS function, self-renew and 
tumorigenic capacity (27). Particularly, PGC1α is associated with mitochondrial biogenesis, 
and maintains the renewal capacity of CSCs, thus favouring the spread of CSCs, tumor 
recurrence and metastasis (25) (28).  The high levels of PGC1α in pancreatic CSC are due to a 
decrease in MYC expression, so that increase the functions performed by PGC1α (25).  
 
4.4. EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) 
In PDAC the process of EMT favours the early spread of tumor cells inducing invasion and 
metastasis (29)(30). Tumor cells decreases the expression of epithelial markers  while 
mesenchymal markers such as SNAIL1, SNAIL2 and ZEB1 increases expression level to 
acquire more mobility and invasiveness, and finally move to a metastatic phenotype (31). When 
they acquire these characteristics they are able to invade nearby tissues, and even pass into the 
bloodstream, reaching more distant areas (14). In cell spread process, cells synthesize 
cytoskeleton filaments to modify the shape of the cell and allow it to move to other regions, for 
the filaments synthesis is necessary large amounts of energy, so the mitochondria must be of 
great importance. 
PDAC tumor presents a high amount of stroma that induces a hypoxic environment, so the EMT 
depends on the level of ROS and TME (32)(33). In a hypoxic situation the mitochondrial protein 
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DRP1 is able to remodel the cytoskeleton and increase the formation of lamellipodia, although 
in normal conditions happen too, so there is an increase in the mobility of microtubules 
depended on mitochondrial dynamics (Figure 3C)(19)(34). 
In more detail, studies ,which compare between metastatic and non-metastatic cells in breast 
cancer, have allowed us to see how there is an increase in the expression of DRP1 and a decrease 
in mitofusins (14). In PDAC, NF-kB recruits and phosphorylates in S616 at DRP1, so this gene 
participates in the increase of mitochondrial fission. However, the increase in mitofusins 
reduces the migration process (14)(13), so there are studies try to study the inhibition of DRP1 
by mDivi-1 because increased mitochondrial fusion and thus slows down migration and tumor 




















In PDAC, the processes of proliferation and new tumor formation in CSCs depend on 
mitochondrial activity. Therefore, our study focuses on the relationship between mitochondrial 
dynamics and the processes of cell pluripotency and migration. We wanted to compare results 
and ideas about the relationship between these processes, so our objectives were the following: 
1. To verify through bioinformatic tools the overexpression of pluripotency genes and see 
its impact on the survival of PDAC patients. 
2. To study the levels of expression of the genes of mitochondrial dynamics in PDAC 
patients and samples enriched in CSCs. 
























 MATERIALS AND METHODS 
6.1. Cell lines 
Cell lines came from patient-derived xenografts (PDX) as tumor pieces. The tumor pieces were 
from Johns Hopkins Hospital (USA) and were isolated from the primary lesions of patient with 
resectable PDAC. Finally, the tumors were spread by Sancho’s group under a procedure 
approved by the Ethics Committee from University of Zaragoza (ref. PI22/17).  
 
6.2.  Cell culture 
All cell lines were maintained in Roswell Park Memorial Institute (RPMI) 1640 (1X) media 
with GlutaMAX (GibcoTM, ThermoFisher Scientific, UK) supplemented with 10% of Fetal 
Bovine Serum (FBS) (GibcoTM, ThermoFisher Scientific, UK) and 1% of 
penicillin/streptomycin (P/S) (Corning, USA). While   Dulbecco’s modified Eagle’s F-12 media 
(DMEM) (GibcoTM, ThermoFisher Scientific, UK) supplemented with 2% B27, 0.02% 
Fibroblast growth factor (FGF) (GibcoTM, ThermoFisher Scientific, UK) and 1% P/S was used 
for experiments. In both cases, the cells were incubated at 37ºC in a humidified incubator 
(Nuaire, USA) with 5% CO2.  On the other hand, sphere cultures were used to obtain a 
population rich in CSCs, so that can be analysed and compared with adherent cells. This process 
was carried out by the group following the guidelines of one of their articles (25). 
 
6.3. Wound healing assay  
The cells were seeded into 24-well plates at a density of 1.5 · 105 cells/well and incubated 5 
days with supplemented RMPI media, to finally obtain a cellular monolayer. The following 
step was changing media, half the wells with DMEM F-12 media, and the other half with 
macrophage-conditioned media (MCM), and the plate was incubated 48 hours more. After that, 
the wound was made with the tip of a 20-μL pipette and washed several times with Phosphate-
buffered saline (PBS) (ThermoFisher Scientific, UK) until complete removal of the dead or 
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unattached cells. After the last wash, the cells were treated with mDivi-1 (Selleckchem, S7172) 
at different concentrations: 0, 20 and 40 μM. The healing status of the wound was observed 
with Nikon Eclipse TS100 inverted binocular microscope (BIRIDEN, Uruguay) and 
photographed at 0h, 24h, 48h and six days after scratching. The scratch area was calculated by 
ImageJ and the wound closure was calculated with the next formula: ((Area 0h – Area 48h) / 
Area 0h) * 100.  
 
6.4. Proliferation assay 
The cells were seeded into 96-well plates at a density of 1.0 · 104 cells/well and incubated for 
24h with supplemented RMPI media. After incubation, the plated cells were treated with 
mDivi-1 (Selleckchem, S7172) in DMEM F-12 media at different concentrations: 0, 20, 40 and 
80 μM. The plate was incubated for 0h, three days and seven days. After that, the cells were 
stained with 0.2% crystal violet (CV) (GibcoTM, ThermoFisher Scientific, USA) for 30-45 
min. After that, we removed the CV with a Pasteur pipette, washed the wells with tap water 
and, finally, we let the plate dry. Once the plate was dried, we added 1% Sodium dodecyl sulfate 
(SDS) and incubated it for 1h. After that, the plate was introduced into the spectrophotometer 
(Synergy HT, BioTek, USA) and absorbance read at 560 nm.  
 
6.5. Real- Time Quantitative Polymerase Chain Reaction (qRT-PCR) 
Previously, Sancho's group prepared the cDNAs of the different cell lines for the qRT-PCR. 
Quantitative real-time PCR was performed using PowerUp SYBR Green Master Mix (Applied 
Biosystem, ThermoFisher Scientific, USA) and detected by StepOnePlusTM Real-Time PCR 
System (Applied BiosystemsTM, ThermoFisher Scientific, USA). The results were normalised 
with Hypoxanthine Phosphoribosyltransferase 1 (HPRT) mRNA for mRNA measurement.  All 
the primers were designed (Thermo Fisher Custom Primers, InvitrogenTM, ThermoFisher 
Scientific, USA) by the director and are shown in Table 1.  Each experiment was repeated two 







PRIMERS REVERSE FORWARD 
HPRT 
CGA GCA AGA CGT TCA 
GTC CT 





PRIMERS REVERSE FORWARD 
12S 
CTA TTG ACT TGG GTT 
AAT CGT GTG A 
CCA CGG GAA ACA GCA GTG 
AT 
DRP1 
AGG CAC CTT GGT CAT 
TCC TG 
AGA AAA TGG GGT GGA AGC 
AGA 
FIS1 
AGG CCT TAA AGT ACG 
TCC GC 
TGC CCA CGA GTC CAT CTT 
TC 
DNM2 
TCT CCC CCT GAT TGG 
GGA TG 
AGA CAG AGC GAA TCG TCA 
CC 
MFN1 
GCC ATT ATG CTA AGT 
CTC CGC 
GCC TCC TCT CCG CCT TTA 
AC 
MFN2 
GTC TCA GGT TGA GGT 
TGG CT 
GGC AGC AGA GGC GTA AGG 
A 
OPA1 
GCG AGG CTG GTA GCC 
ATA TT 




PRIMERS REVERSE FORWARD 
NANOG 
TGC CAC CTC TTA GAT 
TTC ATT CTC T 
AGA ACT CTC CAA CAT CCT 
GAA CCT 
KLF4 
ATG TGT AAG GCG AGG 
TGG TC 





CGG GGC CGG TAT TTA 
TAA TC 
AGA ACC CCA AGA TGC ACA 
AC 
OCT3/4 
CTG CAG TGT GGG TTT 
CGG GCA 
CTT GCT GCA GAA GTG GGT 
GGA GGA A 
 
6.6.  Bioinformatic analysis and pathways construction  
For the box plots comparing gene expression between normal and tumor tissues. We used the 
Pancreatic Adenocarcinoma (PAAD) dataset from The Cancer Genome Atlas Program 
(TCGA), which was compared with normal tissue database from TCGA and Genotype-Tissue 
Expression (GTEx). The box-plots were generated using the GEPIA2 (Gen Expression 
Profiling Interactive Analysis) webtool with Expression DIY tool (http://gepia2.cancer-
pku.cn). The expression data were first log2(TPM+1) transformed and log2FC was defined as 
median of tumor and normal tissue. The method for differential analysis was one-way ANOVA, 
*p ≤ 0.01.  
The correlation plots were generated using PAAD database with TCGA tumor, TCGA normal 
and GTEx dataset, the data were analysed with Pearson correlation coefficient using the non-
log scale for calculation and use the log-scale axis for visualization by GEPIA2 webtool.  
Disease free survival (DFS) plots were generated PAAD dataset with survival plot tool by 
GEPIA2 webtool. The method analysis was Mantel-Cox test, median was selected for splitting 
the high-expression (50%) and low-expression (50%) cohorts and we inclued hazard ratio and 
95% confidence interval. 
The pathway construction was performed using the multiple proteins tool from STRING 
(Search Tool for the Retrieval of Interacting Genes/Proteins, https://string-db.org/) webtool. 
The parametres were: organism = homo-sapiens; meaning of network edges = molecular action; 
active interaction sources = all; minimum required interaction score = medium confidence 
(0.400); max number of interactors to show = none; and network display mode = interactive 
svg. The two parameters to take into account are: the average local clustering coefficient, i.e. 
the closer it is to 1, the probability of interaction is greater; and the other, the protein-protein 
Table 1. Reverse and forward primers used in qRT-PCR 
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interaction (PPI) enrichment p-value, a lower p value means the proteins are more biologically 
connected. 
6.7. Statistical analysis 
The statistical analysis was performed using GraphPad Prism 8.0. The wound healing data was 
analysed by Krustal-Wallis test with α = 0.05. Two-tailed Unpaired T test was used to analyse 
the ratio between fission and fusion genes. Differentiate expression of pluripotency genes was 
assessed by two-tailed Mann Whitney test. Two way-ANOVA was used to analyse the 
expression of mitochondrial dynamic genes, α = 0.05. The proliferation assay was analysed 
with non-linear regression test, the selected equation was the user-defined equation = absolute 
IC50 from normalized data. All data are presented as mean ± SEM. We considered ***p ˂ 



















7.1. Network of connection between mitochondrial dynamics and the 
processes of pluripotency and migration 
Tumors in PDAC are composed of cellular subpopulations, which can be subjected to epithelial-
to-mesenchymal transition to acquire more mobility and invasiveness, eventually achieving an 
aggressive phenotype. Within these subpopulations, CSCs stand out for being undifferentiated 
and for their ability to self-renew.  In addition, they express different genes involved in the 
regulation of pluripotency, NANOG, KLF4, SOX2, and OCT4. Like other tumor cells, CSCs 
can also undergo the EMT process, acquiring an invasive capacity along with the characteristics 
they already possessed. In the other hand, previous studies by the group suggest that the process 
of mitochondrial dynamics may be essential for migration in CSC. Therefore, we wanted to 
study the relationship between the three processes. 
First of all, we wanted to correlate mitochondrial dynamics with the other two pathways. For 
that, we used PAAD database from the TCGA tumor, TCGA normal and GTEx dataset 
correlation web tool by GEPIA2. In the one hand, we tried to correlate mitochondrial dynamics 
(DNM1L, FIS1, DNM2, MFN1, MFN2 and OPA1) with pluripotency genes (NANOG, SOX2, 
KLF4 and OCT4), obtaining very significant positive results (p = 0) (Figure 4A). In the other 
hand, the mitochondrial dynamics and the EMT process (SNAIL1, SNAIL2 and ZEB1)  were 
also correlated and the results were significatively positive (p = 0) (Figure 4B). As described 
by other authors, the correlation between EMT and pluripotency was positive (Figure 1C) (35). 
Once the positive correlation between the processes was confirmed, their connection was 
studied using the multiple proteins options in homo-sapiens organism by STRING. The results 
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for the interaction between the three pathways showed the average local clustering coefficient 
Figure 4. Representative schedule about the mitochondrial interaction with pluripotency and migration process. Correlation graphs 
of A) mitochondrial dynamic and EMT. B) mitochondrial dynamic with pluripotency and C) pluripotency and EMT were obtained with 
Pearson coefficient by GEPIA2 (p = 0). Network connection between D) mitochondrial dynamic, pluripotency, and migration E) 
pluripotency and EMT F) EMT and mitochondrial dynamic and G) pluripotency and mitochondrial dynamic were created by STRING. 
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was 0.838 and the PPI enrichment p-value was <1.0e-16, thus the probability that the interaction 
represented (Figure 4D) between the different proteins was close to maximum confidence.  
As expected, the proteins encoded by the pluripotency genes presented a high number of 
interactions with those encoded by the EMT genes, the average of the resulting clustering 
coefficient was 0.871 and the PPI enrichment p-value was 3.14e-13 (Figure 4E). The interaction 
between mitochondrial dynamics and EMT did not present any point of interaction. However 
the values obtained were really good, because the average of coefficient was 0.844 and the PPI 
enrichment p-value was 2.44e-16 (Figure 1F). In the other hand, mitochondrial dynamic 
proteins presented one point of conection with the proteins encoded by plurpotency genes, the 
average of the resulting clustering coefficient was 0.88 and the PPI enrichment p-value was 
2.22e-16  (Figure 4G). 
Therefore, stemness may be interacting both with the pathway that regulates the EMT and with 
the proteins involved in mitochondrial dynamics. Moreover, with these connections it could be 
said that mitochondrial dynamics and the EMT process are indirectly related.  
 
7.2. Increased expression of pluripotent genes indicates poorer survival 
in PDAC patients 
In PDAC, the presence of CSCs has been associated with ineffective chemotherapy treatments, 
and therefore represents a worse prognosis for patients with chemoresistant tumors. The CSCs 
have different levels of pluripotency gene expression that allow them to be identified. Thus, the 
aim was to evaluate the level of expression of pluripotency genes (NANOG, KLF4, SOX2 and 
OCT4) using expression tool by GEPIA2. The box-plot graphs showed increased expression in 
the tumor tissue with respect to normal tissue. In particular, KLF4 gene was the only one that 
showed a significant increase (p ≤ 0.01) (Figure 5A). However, although the other three genes 
did not show significative results, we were able to see the same tendency in the four genes. In 
addition, analysis of the expression signature of the four genes showed significant 
overexpression in the tumor tissue (p ≤ 0.01) (Figure 5B).   
In addition, we wanted to see if the expression of these genes had an impact on patient survival. 
For these analyses, we used the PAAD database from TCGA, the Kaplan-Meier was obtained 
with the survival plot tool by GEPIA2.  The DFS graph allowed see how the level of expression 
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of pluripotency genes influences the survival rate, in other words, patients with low levels of 
expression survived longer than those with higher levels (Figure 5C). 
As described by Heeschen's group, growth in spheres increases the proportion of CSCs (24). 
Therefore, we wanted to see if our enriched-CSC cultures from PDAC PDX showed an increase 
in the expression of the pluripotency genes with respect to differentiated cells.  
The results obtained by qRT-PCR revealed an increase in the expression of all the genes in 
enriched-CSCs samples, and in particular, NANOG presented a very significant increase in the 
level of expression (p = 0.0006) and OCT4 gene showed a significant increase as well (p = 
0.0291) (Figure 5D).  
 
Figure 5. The expression of pluripotency genes is increased in enriched CSCs, that shows worse survival patients. A) 
Differentiate expression of pluripotency genes and B) signature of pluripotency genes between tumour and normal tissue 
were obtained with one-way ANOVA by GEPIA2. *p ˂ 0.01 C) Kaplan-Meier graph of disease-free survival in PAAD 
showed worse prognosis when there are high level expression of pluripotency genes and was created with Mantel-cox test 
by GEPIA2. D) Expression of pluripotency genes was increased in CSC-enriched samples PDAC, it was analysed by Mann 
Whitney test, ***p ˂ 0.001, *p ˂ 0.05. Data are presented as mean ± SEM. n=7 
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In conclusion, expression of pluripotency genes was increased in PDAC, which was associated 
with reduced survival in patients. On the other hand, sphere culture was a useful model for CSC 
enrichment and because of that, we will use it in the next analysis.  
 
7.3. Increased expression of mitochondrial dynamics genes reveals a 
poor prognosis in PDAC 
Other studies have revealed that mitochondrial dynamics are involved in tumor progression and 
invasion due to a disturbance in the balance between mitochondrial fusion and fission (12). As 
with the pluripotency genes, their expression was analysed in both normal and tumor tissue 
with Expression DIY tool in PDAC patients by GEPIA2. The mitochondrial fission genes 
(DRP1, FIS1 and DNM2) were significantly (p ≤ 0.01) increased in the tumor tissue with respect 
to normal (Figure 6A). However, while one of the genes involved in mitochondrial fusion 
(MFN1)  exhibited low levels of expression in tumor tissue, the other fusion genes, MFN2 and 
OPA1, were expressed significantly more in tumor (Figure 6B).  
Although there were differences in expression individually, the joint signature of the six genes 
indicated a significant increase in PDAC (Figure 6C). DFS graph obtained by GEPIA2 showed 
that expression levels of mitochondrial dynamics genes had an impact on survival.  The survival 
graphs for the signature of mitochondrial dynamics (p = 0.44) indicated that patients tended to 
have a higher survival when the expression levels of mitochondrial dynamics were low, while 
when its expression was high it had a negative impact on survival (Figure 6D).  This was also 
observed significantly in the mitochondrial fusion graph (p = 0.013) (Figure 6F). However, the 
fission gene survival graph (p = 0.22) showed that patients tended to have better survival when 
expression levels were increased, while at low levels, patients had a worse prognosis (Figure 
6E).  
In conclusion, the genes of mitochondrial dynamics were, for the most part, overexpressed in 





Figure 6. Mitochondrial dynamics gene expression is increased in tumoral tissue and predicts worse survival in patients. 
A) expression of individual mitochondrial fission genes B) individual mitochondrial fusion genes C) signature of 
mitochondrial genes. Differences between tumour and normal tissue were analysed with one-way ANOVA by GEPIA2. *p 
˂ 0.01 D-F) Kaplan-Meier graph of disease-free survival in PAAD analysed with Mantel-cox Test by GEPIA2. D) Survival 
graphs of signature of mitochondrial genes and F) mitochondrial fusion genes (MFN1, MFN2 AND OPA1) showed worse 
prognosis when they are more expressed. E) Survival graph of fission genes (DNM1L, FIS1 and DNM2) showed worse 
prognosis when they are less expressed.  
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7.4. The ratio of mitochondrial fission to fusion is increased in CSC-
enriched conditions.  
Studies have shown that mitochondrial fission is involved in cell reprogramming, and the DRP1 
gene is crucial for the development and maintenance of pluripotency. Particularly, DRP1 
maintains the self-renewal capacity of CSC (14). Our first aim was to test whether the increased 
expression of the mitochondrial dynamic genes seen in the previous bioinformatic analysis in 
PDAC is observed in both differentiated cells and CSC-enriched samples. The samples had 
been previously selected for their overexpression of pluripotency.  
 
The results obtained were as follows: the PDX-185 line didn´t show an overexpression of the 
genes in the CSC sample, except for FIS1 (Figure 7A); the PDX-253 line showed overexpressed 
genes such as FIS1, DNM2, MFN1 and OPA1 and others such as DRP1 and MFN2 that were 
expressed to a lesser extent (Figure 7B); the PDX-215 line showed an overexpression of all 
genes so that CSC cells had higher levels of expression of mitochondrial dynamics (Figure 7C); 
the last line, PDX-354, presented an over-expression of the fusion genes while the fission genes 
were expressed less than in adherents cells (Figure 7D). Of the analyses performed for each 
Figure 7. The expression of mitochondrial dynamic genes is increased in enriched-CSC samples. Expression of 
mitochondrial dynamic genes in CSC vs differentiated cells in A) PDX-185 n=1 B) PDX-253 n=1 C) PDX-215 n=3 
D) PDX-354 n=2. We used two-way ANOVA for statistical analysis. Data are presented as mean ± SEM.  
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line, those obtained in PDX-215 are the most reliable since it was tripled, however, the PDX-
354 line was duplicated and PDX-185 and 253 were only analysed once.  
The lack of biological replicates in some lines and the different levels of expression in each cell 
line did not indicate anything conclusive. Due to that, a second analysis was proposed, aiming 
to analyse the relationship between fusion and mitochondrial fission.  The results showed that 
PDX-185, 253 and 215 lines tended to have higher fission in CSC-enriched conditions. In fact, 
as mentioned above, mitochondrial fission is present in reprogramming processes of CSC, 
therefore, it was expected to be increased (Figure 8). Statistical analyses were not significant 
due to the low number of replicates.  
 
7.5. Overexpression of genes involved in the epithelial-to-mesenchymal 
transition in PDAC reveals a worse prognosis. 
Invasion and migration out of the primary tumor is seen in many cancers, in PDAC it is usually 
due to the EMT process, although some studies reveal that the process of metastasis is not 










































Figure 8. The ratio between fission and fusion genes is increased 
in enriched-CSC samples. The ratio was calculated by dividing 
fission versus fusion. The mitochondrial fission value was 
calculated as mean of DRP1, FIS1 and DNM2 ΔCTs, and for 
mitochondrial fusion, the mean of MFN1, MFN2 and OPA1 ΔCTs 
in both enriched-CSCs and differentiated cell samples. Data 
obtained are presented as mean and analysed by unpaired T test 
for PDX-215. (PDX-185) n=1, (PDX-253) n=1, (PDX-354) n=2 
and (PDX-215) n=3  
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mesenchymal markers such as SNAIL1, SNAIL2 and ZEB1 increase their level of expression.  
For that, first of all, we wanted to compare the levels of expression of the genes SNAIL1, 
SNAIL2 and ZEB1 between tumor tissue and normal tissue using the bioinformatics tool 




The results showed a significant increase (p ≤ 0.01) in the expression of the three genes in tumor 
tissue (Figure 9A), and analysis of the expression signature of the three genes also showed a 
significant increase (Figure 9B). The survival graph (p = 0.018) indicated that at higher levels 
of expression patients had a worse prognosis, but when the levels of expression were low the 
survival was better (Figure 9C).  
Figure 9. The expression of EMT genes is increased in tumoral tissue and predicts worse survival in patients. 
A) Expression of individual EMT genes and B) signature of EMT genes between tumour and normal tissue, 
analysed with one-way ANOVA by GEPIA2. *p ˂  0.01 C) Kaplan-Meier graph of disease-free survival in PDAC 
showed worse prognosis when there is high expression level of EMT genes and was analysed with Mantel-cox 
test by GEPIA2. 
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In conclusion, PDAC tumors presented higher levels of mesenchymal markers, and its 
increased expression indicated worse survival.  
 
7.6. Inhibition of DRP1 by mDivi1 induces a decrease in cell migration 
in PDAC  
The interaction network of Figure 4D showed that there was no direct interaction between 
mitochondrial dynamics and the process of EMT. However, several studies indicate that the 
mitochondrial fragmentation is associated with cell invasion: the researchers have seen that 
high levels of DRP1 increase migration. Moreover, when DRP1 is inhibited cellular migration 
decreased (14).  
With this idea, we wanted to see, first, if there was a correlation between mitochondrial fission 
with EMT (Figure 10A), especially with the DRP1 gene (Figure 10B). The correlation analysis 
was performed with TCGA and GTEx database with PDAC database by GEPIA. The results 
showed a positive correlation in both cases. 
The next experiment was a proliferation assay to determine the percentage of celular death or 
celular proliferation with respect to the different doses of an inhibitor of DRP1, called mDivi-
1. The graph showed how the percentage of proliferation decreased when the dose was 
increased, however, this also revealed the suitable non-lethal dose and treatment time for future 
trials (Figure 10C). 
Cellular migration was evaluated by wound healing assay. For this, the cells were in two 
different conditions: on the one hand, they were in MCM, which was rich in cytokines to 
promote the activation of the EMT process and, on the other hand, without this enrichment. In 
the magnified image of this control we was be able to see the stellate morphology that the cells 
acquired during this process (Figure 10D). The images showed how the wound remained open 
after 48h, when mDivi-1 was added. However, in the control of enrichment media we was able 
to see how the wound had closed almost completely (Figure 10E). The percentage of wound 
closure decreased when  the concentration of mDivi-1 increased,  especially in the medium 
enriched with MCM (Figure 10F). 
Therefore, mDivi-1 inhibited cell migration. This migration inhibition was more pronounced in 




Figure 10. Inhibition of Drp1 with mDivi1 decrease the migration process of PDAC cells. Correlation graphs of A) 
mitochondrial fission (DRP1, FIS1and DNM2) and EMT B) DRP1 with pluripotency were analysed with Pearson 
coefficient by GEPIA2 (p = 0). C) Proliferation assay showed that mDivi-1 inhibits the proliferation of PDAC cells. Data 
are presented as mean ± SEM. n=3, we analysed with Kruskal Wallis test D) Magnified image of control with MCM showed 
how the cells acquired stellate morphology. E-F) Wound healing assay confirmed that mDivi-1 could decrease the 




Mitochondria generate the energy needed for all cellular processes, including proliferation, 
migration or survival (13). In these processes, the mitochondria morphology is modified by 
mitochondrial fusion or fission proteins, depending on the process or cellular conditions, in 
which cells are at that moment (19)(23). Structural change occurs by the balanced action of 
mitochondrial fission and fusion, and its deregulation would lead to metabolic dysfunction 
resulting in disease (13)(19). During this dysfunction, the cells suffer a situation of stress that 
induces the process of senescence in which the cells try to recover the mitochondrial balance. 
However, in PDAC, due to the accumulation of mutations that it presents, the cells may be 
susceptible to other processes such as cell reprogramming or EMT (8)(36)(37)(38). In PDAC, 
the presence of CSCs is associated with therapeutic resistance, and if these cells are subjected 
to EMT, their invasion into other areas is facilitated. The group found that the migration of 
CSCs depends on the mitochondrial fission process, which is consistent with the importance of 
mitochondrial dynamics in tumor progression, as explained by other authors (12).  
 
Our study shows that overexpression of the genes for mitochondrial dynamics, pluripotency 
and EMT is associated with a worse prognosis in patients with PDAC. The molecular 
connection between the three processes has not been determined yet, but our aim was to study 
the relationship between them. Finally, our interaction network showed that there is connection 
between the three processes. The association between the pluripotency process and EMT is very 
close, SNAIL1 has an activating effect on ZEB1 and NANOG, acting also at the level of 
transcriptional regulation. Studies have shown the interaction between NANOG with the factors 
SNAIL1 and SNAIL2 during cell reprogramming (39). On the other hand, ZEB1 has been shown 
to inhibit the miR-200 family which represses the epigenetic regulator BMI1, therefore, the 
miR-200/Zeb1 axis controls the switch between stemness and differentiated cell particularly in 
pancreatic CSCs (31)(35)(38). 
Several studies have shown the connection between mitochondrial dynamics and CSCs. 
Mitochondrial fission is involved in cell reprogramming, and the DRP1 gene is crucial for the 
development and maintenance of pluripotency. Moreover, the DRP1 gene plays an important 
role in the cell cycle, which is associated with the process of self-renewal, characteristic of these 
CSCs (14). On the other hand, studies on the epigenetic regulation of CSCs reveal that in normal 
breast tissue the repression of the miR-200 family, described previously, acts in another way 
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where it activates PGC1α which co-activates MFN1 in charge of regulating the asymmetric cell 
division that allows maintaining the renewal capacity of stem cells (35). Importantly, PGC1α 
is associated in PDAC, with mitochondrial biogenesis, which regulates the self-renewal 
capacity of CSCs, thus favouring the spread of CSCs, tumor recurrence and metastasis (25)(28).  
Our results obtained by PCR did not reveal any difference between mitochondrial fission and 
fusion in CSCs. Perhaps the lack of biological samples is the cause, so an analysis with a larger 
number of samples would have determined which mitochondrial process was predominant and 
could have shown a clear profile in PDAC. However, the ratio of fission to fusion revealed an 
increase in the mitochondrial dynamics of PDAC CSC-enriched samples. This is to be expected 
since, as commented above, mitochondrial dynamics are closely linked to cell reprogramming 
(40). To accurately determine the predominant dynamics of each cell group, further analysis 
must be performed. 
Nevertheless, there is evidence that the difference in expression of mitochondrial dynamics 
affects tumor development and profile.  Increased mitochondrial fission frequently occurs in 
cancer, and is due to overexpression of DRP1, this fact promotes metastasis in breast cancer 
and favours liver tumor cell survival (12)(13) Increased DRP1 is also associated with actin 
filaments which are involved in the movement of cells to other regions (13). However, the 
decrease in MFN1 or MFN2 favours the proliferation, invasion and migration of tumor cells 
(12). These facts were verified, when there is overexpression of MFN1 or MFN2 or inhibition 
of DRP1 a decrease in migration and invasive potential of tumor cells was seen (13).  
Although the connection network does not show interaction between EMT and mitochondrial 
dynamics. Other studies reveal that pancreatic tumor cells have high mitochondrial 
fragmentation, associated with tumor migration and invasion (18). Our studies reveal that 
inhibition of DRP1 by mDivi-1 slows down the cell migration process. Therefore, the drug 
inhibits the migration process, but the lack of statistical analysis does not determine anything 
conclusive. However, other studies show that mDivi-1 by inhibiting mitochondrial fission 
promotes mitochondrial fusion and affects outside the mitochondria in a way that stops the cell 
cycle. It would be interesting to study it under hypoxic conditions, since MSDs and ROS levels 
are associated with the EMT process in PDAC. mDivi1 in different studies has shown that it 
only affects the survival and proliferation of transformed cells, but it is still being studied 
because its effects depend on cell type and type of disease (18)(13).  
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In conclusion, although the exact molecular mechanism by which mitochondrial dynamics 
influences the processes of pluripotency and EMT is not known, it is known that there is a 
certain interaction, as has been seen so far. In PDAC, genes such as PGC1α are the link between 
mitochondrial biogenesis and CSCs, and the increase in mitochondrial dynamics in CSCs 
enhances the connection between both processes. On the other hand, the molecular connection 
between mitochondrial dynamics and EMT remains unknown. However, the inhibition of the 
migration process by the DRP1 inhibitor directed to the mitochondrial dynamics of tumor cells 
reveals that both processes are related. 
Therefore, the importance of mitochondrial biogenesis in stemness and EMT allows studying 
possible treatments focused on mitochondrial dynamics, so that in the future it is possible to 
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